Extracellular Vesicles (EVs) Derived from Mesenchymal Stem Cells (MSCs) as Adjuvants in the Treatment of Chronic Kidney Disease (CKD)
Chronic kidney disease (CKD) is considered an important health issue worldwide. The renin–angiotensin–aldosterone system (RAAS) blockade through the administration of angiotensin II receptor blockers, such as Losartan (LOS), has been considered the best strategy for CKD treatment for decades. Howeve...
Saved in:
| Main Authors: | , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
MDPI AG
2025-03-01
|
| Series: | Cells |
| Subjects: | |
| Online Access: | https://www.mdpi.com/2073-4409/14/6/434 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1849342938098696192 |
|---|---|
| author | Paloma Noda Ana L. R. Francini Flavio Teles Samuel J. Júnior Fernando L. A. Fonseca Fernanda T. Borges Adão C. Sobrinho Noemi Taniwaki Irene L. Noronha Camilla Fanelli |
| author_facet | Paloma Noda Ana L. R. Francini Flavio Teles Samuel J. Júnior Fernando L. A. Fonseca Fernanda T. Borges Adão C. Sobrinho Noemi Taniwaki Irene L. Noronha Camilla Fanelli |
| author_sort | Paloma Noda |
| collection | DOAJ |
| description | Chronic kidney disease (CKD) is considered an important health issue worldwide. The renin–angiotensin–aldosterone system (RAAS) blockade through the administration of angiotensin II receptor blockers, such as Losartan (LOS), has been considered the best strategy for CKD treatment for decades. However, this approach promotes only partial detention of CKD progression and cannot reverse renal damage. The aim of the present study was to investigate whether the therapeutic administration of extracellular vesicles (EVs) derived from adipose stem cells (ASCs), associated to LOS treatment, would promote additional renoprotection in rats underwent the 5/6 renal ablation CKD model. ASC-derived EV were administered locally, in the renal subcapsular area, 15 days after CKD induction, when LOS therapy also began. Animals were followed for additional 15 days and our results demonstrated that subcapsular injection of ASC-derived EV associated with LOS significantly reduced glomerulosclerosis, renal interstitial infiltration by myofibroblasts, and macrophages in the 5/6 CKD model. Additionally, LOS + EV abrogated systemic hypertension, proteinuria, and albuminuria, and stimulated local gene overexpression of the endogenous anti-inflammatory <i>Il-4</i>. Although more studies are still required to establish the best EV dose and administration route, these findings point to therapy with ASC-derived EV as a potential adjuvant in CKD treatment |
| format | Article |
| id | doaj-art-c8000f3b29d8416fac52ddcd72735f4b |
| institution | Kabale University |
| issn | 2073-4409 |
| language | English |
| publishDate | 2025-03-01 |
| publisher | MDPI AG |
| record_format | Article |
| series | Cells |
| spelling | doaj-art-c8000f3b29d8416fac52ddcd72735f4b2025-08-20T03:43:11ZengMDPI AGCells2073-44092025-03-0114643410.3390/cells14060434Extracellular Vesicles (EVs) Derived from Mesenchymal Stem Cells (MSCs) as Adjuvants in the Treatment of Chronic Kidney Disease (CKD)Paloma Noda0Ana L. R. Francini1Flavio Teles2Samuel J. Júnior3Fernando L. A. Fonseca4Fernanda T. Borges5Adão C. Sobrinho6Noemi Taniwaki7Irene L. Noronha8Camilla Fanelli9Laboratory of Cellular, Genetic and Molecular Nephrology, Renal Division, Faculty of Medicine, University of São Paulo, Av. Dr. Arnaldo, 455, 4° Andar, 4304, São Paulo 01246-903, SP, BrazilLaboratory of Cellular, Genetic and Molecular Nephrology, Renal Division, Faculty of Medicine, University of São Paulo, Av. Dr. Arnaldo, 455, 4° Andar, 4304, São Paulo 01246-903, SP, BrazilRenal Division, Faculty of Medicine, Federal University of Alagoas, Maceio 57200-000, AL, BrazilLaboratory of Cellular, Genetic and Molecular Nephrology, Renal Division, Faculty of Medicine, University of São Paulo, Av. Dr. Arnaldo, 455, 4° Andar, 4304, São Paulo 01246-903, SP, BrazilDepartment of Clinical Laboratory, University Center of ABC Medical School, Santo Andre 09060-650, SP, BrazilDepartament of Medicine, Nephrology Division, Paulista School of Medicine, Federal University of São Paulo, São Paulo 04023-062, SP, BrazilLaboratory of Cellular Biology, Department of Pathology, School of Medicine, University of São Paulo, São Paulo 01246-903, SP, BrazilLaboratory of Electron Microscopy, Instituto Adolfo Lutz, São Paulo 01246-000, SP, BrazilLaboratory of Cellular, Genetic and Molecular Nephrology, Renal Division, Faculty of Medicine, University of São Paulo, Av. Dr. Arnaldo, 455, 4° Andar, 4304, São Paulo 01246-903, SP, BrazilLaboratory of Cellular, Genetic and Molecular Nephrology, Renal Division, Faculty of Medicine, University of São Paulo, Av. Dr. Arnaldo, 455, 4° Andar, 4304, São Paulo 01246-903, SP, BrazilChronic kidney disease (CKD) is considered an important health issue worldwide. The renin–angiotensin–aldosterone system (RAAS) blockade through the administration of angiotensin II receptor blockers, such as Losartan (LOS), has been considered the best strategy for CKD treatment for decades. However, this approach promotes only partial detention of CKD progression and cannot reverse renal damage. The aim of the present study was to investigate whether the therapeutic administration of extracellular vesicles (EVs) derived from adipose stem cells (ASCs), associated to LOS treatment, would promote additional renoprotection in rats underwent the 5/6 renal ablation CKD model. ASC-derived EV were administered locally, in the renal subcapsular area, 15 days after CKD induction, when LOS therapy also began. Animals were followed for additional 15 days and our results demonstrated that subcapsular injection of ASC-derived EV associated with LOS significantly reduced glomerulosclerosis, renal interstitial infiltration by myofibroblasts, and macrophages in the 5/6 CKD model. Additionally, LOS + EV abrogated systemic hypertension, proteinuria, and albuminuria, and stimulated local gene overexpression of the endogenous anti-inflammatory <i>Il-4</i>. Although more studies are still required to establish the best EV dose and administration route, these findings point to therapy with ASC-derived EV as a potential adjuvant in CKD treatmenthttps://www.mdpi.com/2073-4409/14/6/434extracellular vesicleschronic kidney diseasecell therapymesenchymal stem cells |
| spellingShingle | Paloma Noda Ana L. R. Francini Flavio Teles Samuel J. Júnior Fernando L. A. Fonseca Fernanda T. Borges Adão C. Sobrinho Noemi Taniwaki Irene L. Noronha Camilla Fanelli Extracellular Vesicles (EVs) Derived from Mesenchymal Stem Cells (MSCs) as Adjuvants in the Treatment of Chronic Kidney Disease (CKD) Cells extracellular vesicles chronic kidney disease cell therapy mesenchymal stem cells |
| title | Extracellular Vesicles (EVs) Derived from Mesenchymal Stem Cells (MSCs) as Adjuvants in the Treatment of Chronic Kidney Disease (CKD) |
| title_full | Extracellular Vesicles (EVs) Derived from Mesenchymal Stem Cells (MSCs) as Adjuvants in the Treatment of Chronic Kidney Disease (CKD) |
| title_fullStr | Extracellular Vesicles (EVs) Derived from Mesenchymal Stem Cells (MSCs) as Adjuvants in the Treatment of Chronic Kidney Disease (CKD) |
| title_full_unstemmed | Extracellular Vesicles (EVs) Derived from Mesenchymal Stem Cells (MSCs) as Adjuvants in the Treatment of Chronic Kidney Disease (CKD) |
| title_short | Extracellular Vesicles (EVs) Derived from Mesenchymal Stem Cells (MSCs) as Adjuvants in the Treatment of Chronic Kidney Disease (CKD) |
| title_sort | extracellular vesicles evs derived from mesenchymal stem cells mscs as adjuvants in the treatment of chronic kidney disease ckd |
| topic | extracellular vesicles chronic kidney disease cell therapy mesenchymal stem cells |
| url | https://www.mdpi.com/2073-4409/14/6/434 |
| work_keys_str_mv | AT palomanoda extracellularvesiclesevsderivedfrommesenchymalstemcellsmscsasadjuvantsinthetreatmentofchronickidneydiseaseckd AT analrfrancini extracellularvesiclesevsderivedfrommesenchymalstemcellsmscsasadjuvantsinthetreatmentofchronickidneydiseaseckd AT flavioteles extracellularvesiclesevsderivedfrommesenchymalstemcellsmscsasadjuvantsinthetreatmentofchronickidneydiseaseckd AT samueljjunior extracellularvesiclesevsderivedfrommesenchymalstemcellsmscsasadjuvantsinthetreatmentofchronickidneydiseaseckd AT fernandolafonseca extracellularvesiclesevsderivedfrommesenchymalstemcellsmscsasadjuvantsinthetreatmentofchronickidneydiseaseckd AT fernandatborges extracellularvesiclesevsderivedfrommesenchymalstemcellsmscsasadjuvantsinthetreatmentofchronickidneydiseaseckd AT adaocsobrinho extracellularvesiclesevsderivedfrommesenchymalstemcellsmscsasadjuvantsinthetreatmentofchronickidneydiseaseckd AT noemitaniwaki extracellularvesiclesevsderivedfrommesenchymalstemcellsmscsasadjuvantsinthetreatmentofchronickidneydiseaseckd AT irenelnoronha extracellularvesiclesevsderivedfrommesenchymalstemcellsmscsasadjuvantsinthetreatmentofchronickidneydiseaseckd AT camillafanelli extracellularvesiclesevsderivedfrommesenchymalstemcellsmscsasadjuvantsinthetreatmentofchronickidneydiseaseckd |